ГоловнаArchive of numbers2019Volume 27, issue 3 (100) Possibilities of optimizing approaches to the treatment of resistant epilepsy in children using pharmacogenetic studies data
Title of the article Possibilities of optimizing approaches to the treatment of resistant epilepsy in children using pharmacogenetic studies data
Authors Tantsura Lyudmyla
Pylypets Olena
Tantsura Yevgen
Tretiakov Dmytro
In the section The Scientifi c and Practical Conference proceedings "Modern Approaches to the Diagnosis and Treatment of Nervous System Diseases in Children", September 19—20, Kharkiv
Year 2019 Issue Volume 27, issue 3 (100) Pages 92-96
Type of article Scientific article Index UDK 615.853-056.7:616.08-039:615.355-08 Index BBK -
Abstract We conducted an observation of 83 children with therapy-resistant forms of epilepsy between the ages of 11 months and 18 years. The presence of CYP2C9, CYP2C19 and CYP3A4 gene polymorphisms was detected in 60 of the examined patients, that is, 72.29 % of them, 33 patients (39.76 %) had CYP2C19 gene polymorphisms, CYP2C9 gene polymorphisms had 17 (20.48 %) children, and 10 (12.05 %) of them had CYP3A4 gene polymorphisms. The frequency of CYP2C19*2 and CYP3A4*1B polymorphisms was signifi cantly higher than in the Ukrainian and other European populations, no statistical data signifi - cance of differences in the frequency of CYP2C9 gene polymorphisms compared with the Ukrainian population was found. CYP2C19 gene polymorphisms are signifi cantly more frequently recorded by us compared to the results obtained by researchers in Russia and Turkey in closely related studies. It is shown that children with cytochrome P450 gene polymorphisms are recommended: more frequent clinical, instrumental, and laboratory monitoring of patients to prevent side eff ects of therapy; monitoring (not a one-time study) of AED concentration in blood plasma. The necessity of conduction of pharmacogenetic research at the stage of debut of epilepsy in the case of suspicion of treatment-resistant form of the disease and in the case of ineffi - ciency or severe side eff ects of the fi rst assigned AED was demonstrated.
Key words children, treatment, resistant epilepsy, cytochrome P450, gene polymorphism.
Access to full text version of the article pdf download
Bibliography

1. Shorvon S. Handbook of epilepsy treatment. 3rd ed. Singapore : Wiley-Blackwell, 2010; 75—146.
2. Effect of dosage failed of first antiepileptic drug on subsequent outcome / Brodie M. J., Barry S. J., Bamagous G. A. [et al.] // Epilepsia. 2013; 54: 194—198.
3. Treatment outcome after failure of a first antiepileptic drug / [Bonnett L. J., Turud Smith C., Donegan S., Marson A. G.] // Neurology. 2014; 83(6): 552—560. DOI: 10.1212/WNL.0000000000000673.
4. Kwan P., Brodie M. J. Early identification of refractory epilepsy // N Engl J Med. 2000, Feb 3; 342(5): 314—9. DOI: 10.1056/ NEJM200002033420503.
5. The consequences of refractory epilepsy and its treatment / Laxer K. D., Trinka E., Hirsch L. J. [et al.] // Epilepsy Behav. 2014 Aug; 37: 59—70. DOI: 10.1016/j.yebeh.2014.05.031.
6. The clinical impact of cytochrome P450 polymorphisms on the anti-epileptic drug therapy / Saruwatari J., Ishitsu T., Seo T. [et al.] // Epilepsy Seizure. 2010; 3: 34—50. DOI:https://doi.org/10.3805/eands.3.34.
7. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications // Clin. Pharmacokinet. 2007; 46: 271—279. DOI: 10.2165/00003088-200746040-00001.
8. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3 / Brandolese R., Scordo M. G., Spina E. [et al.] // Clin. Pharmacol. Ther. 2001; 70(4): 391—394. PMID: 11673755.
9. Genetic poly morphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication / Ninomiya H., Mamiya K., Matsuo S. [et al.] // Ther. Drug Monit. 2000; 22(2): 230—232. PMID: 10774639.
10. Dmitrenko D. V. Geneticheskie osobennosti metabolizma valproatov kak faktor riska razvitiya nezhelatelnyh lekarstvennyh yavlenij // Sovremennye problemy nauki i obrazovaniya. 2015. № 5. S. 237.
11. Kresyun V. J., Antonenko P. B. Polimorfizm genu citohromu-450 2S19 na pivdennomu zahodi Ukrayini // Zaporozhskij medicinskij zhurnal. 2011. № 13 (6). S. 36—38.
12. Poludenko H. O., Antonenko P. B. An impact of CYP3A4*1B polymorphism on rifampicin metabolism // Journal of Education, Health and Sport. 2017; 7(8): 1082—1090.
13. Pharmacogenetically relevant polymorphisms in Portugal / Oliveira E., Marsh S., van Booven D. J. [et al.] // Pharmacogenomics. 2007; 8: 703—712. DOI: 10.2217/14622416.8.7.703.
14. Prevalence of CYP2C9 polymorphisms in the south of Europe / Sanchez-Diz P., Estany-Gestal A., Aguirre C. [et al.] // Pharmacogenomics J. 2009; 9: 306—310. DOI: 10.1038/tpj.2009.16.
15. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations / Yang J. Q., Morin S., Verstuyft C. [et al.] // Fundam Clin Pharmacol. 2003; 17: 373—376. PMID: 12803577. 16. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina / Semiz S., Dujić T., Ostanek B. [et al.] // Med Glas (Zenica). 2011; 8(1): 84—9. PMID: 21263403.
17. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population / Bozina N., Granic P., Lalic Z. [et al.] // Croat Med J. 2003; 44: 425—428. PMID: 12950145.
18. Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain / Llerena A., Alvarez M., Dorado P. [et al.] // Pharmacogenomics J. 2014; 14: 229—234. DOI: 10.1038/tpj.2013.28.
19. Rosemary J. Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance // Curr Clin Pharmacol. 2007; 2(1): 93—109. PMID: 18690857.
20. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population / Gaikovitch E. A., Cascorbi I., Mrozikiewicz P. M. [et al.] // Eur J Clin Pharmacol. 2003; 59(4): 303—12. DOI: 10.1007/s00228-003-0606-2.
21. Levkovich N. M., Gorovenko N. G. Harakteristika genetichnoyi strukturi naselennya Ukrayini za polimorfnimi variantami geniv sistemi detoksikaciyi ksenobiotikiv // Faktori eksperimentalnoyi evolyuciyi organizmiv. 2014. № 14. S. 208—211.
22. Guzeva O. V. Optimizaciya diagnostiki i obosnovanie personificirovannoj terapii epilepsii u detej : dis. na soiskanie uch. stepeni doktora med. nauk : 14.01.11 : zashishen. 14.04.14 : utverzhd. 23.09.14 / Guzeva Oksana Valentinovna. SPb., 2014. 266 s.
23. The Effect of Genetic Polymorphisms of Cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on Drug-Resistant Epilepsy in Turkish Children / Seven Mehmet, Bahadir Batar, Selin Unal [et al.] // Molecular Diagnosis & Therapy. 2014; 18(2): 229—236.